Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Eerste studie naar neoadjuvante immuuntherapie bij PCC van start
apr 2021 | Dermato-oncologie, Immuuntherapie